Literature DB >> 6972907

Late treatment of murine lupus erythematosus with dactinomycin. II. C1 and antibody to DNA.

C T Olsen, P O Teague, A E Gabrielsen.   

Abstract

(NZB x NZW)F1 hybrid (B/W) female mice were treated intermittently with dactinomycin beginning at 6--6.5 months of age. Survival was greatly prolonged relative to control mice. IgG antibody to DNA did not decline significantly in the treated mice until they were more than 18 months old, but circulating levels of the first complement component (Cl) rose during the first 4 weeks of treatment and were back into the normal range after 8 weeks. Thus these two humoral indexes of disease activity varied independently, and only Cl reflected the improved status of the treated mice.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6972907      PMCID: PMC1555012     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  10 in total

1.  Complement-dependent alterations in the handling of immune complexes by NZB/W mice.

Authors:  G W Miller; A D Steinberg; I Green; V Nussenzweig
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

2.  DNA-binding assay for detection of anti-DNA antibodies in NZB-NZW F1 mice.

Authors:  A D Steinberg; T Pincus; N Talal
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

3.  Prostaglandin E treatment of NZB/NZW mice.

Authors:  R B Zurier; D M Sayadoff; A B Torrey; N F Rothfield
Journal:  Arthritis Rheum       Date:  1977-03

4.  Early complement components in NZB/NZW mice. I. The first component.

Authors:  C T Olsen; A E Gabrielsen
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

5.  Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique.

Authors:  L A Aarden; E R de Groot; T E Feltkamp
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

6.  Delayed androgen treatment prolongs survival in murine lupus.

Authors:  J R Roubinian; N Talal; J S Greenspan; J R Goodman; P K Siiteri
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

7.  Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone.

Authors:  S E Walker; M R Anver
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

8.  Thiamphenicol and lupus nephritis. The effects of long-term therapy on kidney function and pathology: a pilot study.

Authors:  L O Simpson; I Aarons; J B Howie
Journal:  Br J Exp Pathol       Date:  1979-02

9.  Late treatment of murine lupus erythematosus with dactinomycin (actinomycin D). I. Course and longevity.

Authors:  A E Gabrielsen; C T Olsen
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

10.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains.

Authors:  B S Andrews; R A Eisenberg; A N Theofilopoulos; S Izui; C B Wilson; P J McConahey; E D Murphy; J B Roths; F J Dixon
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.